Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kimberly Manhard"'
Publikováno v:
Journal of Clinical Pharmacology
The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0e651479fbd56b52b7d7d3b00667397
https://doi.org/10.1002/jcph.1124
https://doi.org/10.1002/jcph.1124
Autor:
Michael Lauw, Thomas Ottoboni, Kimberly Manhard, Barry D. Quart, Neil J. Clendeninn, Matt Cravets, Mary Rose Keller
Publikováno v:
Future oncology (London, England). 15(8)
Aim: HTX-019 (CINVANTI® [aprepitant injectable emulsion]) is a neurokinin 1 receptor antagonist approved for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). HTX-019 is free of polysorbate 80 and other synthetic surfacta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::320ce5d8400f647ab1297a4dc601e883
https://pubmed.ncbi.nlm.nih.gov/32631101
https://pubmed.ncbi.nlm.nih.gov/32631101
Autor:
Kimberly Manhard, Michael Lauw, Mary Rose Keller, Neil J. Clendeninn, Barry D. Quart, Tom Ottoboni, Matt Cravets
Publikováno v:
Future oncology (London, England). 14(27)
Aim: Evaluate safety of HTX-019, a novel polysorbate 80– and synthetic surfactant-free intravenous formulation of neurokinin 1 receptor antagonist aprepitant for chemotherapy-induced nausea and vomiting. Methods: Two open-label, randomized, two-way
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9b5973984e314efed0fdfb9df1482e1
https://pubmed.ncbi.nlm.nih.gov/29873529
https://pubmed.ncbi.nlm.nih.gov/29873529
Autor:
Colin Edward Rowlings, Vijay Hingorani, Kimberly Manhard, C. Storgard, Zancong Shen, Brad Kerr, Li-Tain Yeh, Barry D. Quart
Publikováno v:
Drug Design, Development and Therapy
Zancong Shen, Colin Rowlings, Brad Kerr, Vijay Hingorani, Kimberly Manhard, Barry Quart, Li-Tain Yeh, Chris Storgard Ardea Biosciences, Inc. (a member of the AstraZeneca group), San Diego, CA, USA Abstract: Lesinurad is a selective uric acid reabsorp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc99c7830ed003b252867a2a1d299df
http://europepmc.org/articles/PMC4494180
http://europepmc.org/articles/PMC4494180
Autor:
Roy Fleischmann, Bradley Kerr, Matt Suster, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Kimberly Manhard, Elizabeth Polvent, Barry D. Quart, Scott Baumgartner, Vijay Hingorani
Publikováno v:
Rheumatology. 53:2167-2174
Objective. The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1c255ca16bb15e121b3ae4a165ac2d
https://doi.org/10.1093/rheumatology/ket487
https://doi.org/10.1093/rheumatology/ket487
Autor:
David T. Hagerty, Payal Nanavati, Philip K. Tan, Li-Tain Yeh, Barry D. Quart, Jean-Luc Girardet, Kimberly Manhard, Sha Liu, Robert Terkeltaub, Jeffrey N. Miner, Cory Iverson, David Hyndman, Zancong Shen
Publikováno v:
Arthritis Research & Therapy
Arthritis research & therapy, vol 18, iss 1
Arthritis research & therapy, vol 18, iss 1
Background Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9b4abb86e3a95270b00e9d402aec30
https://pubmed.ncbi.nlm.nih.gov/27733209
https://pubmed.ncbi.nlm.nih.gov/27733209
Autor:
Lawrence Garbo, Alex A. Adjei, Li Tain Yeh, Prabhu Rajagopalan, Zancong Shen, Kimberly Manhard, Heiko Krissel, Anthony B. El-Khoueiry, Donald A. Richards, Neil J. Clendeninn, Cory Iverson, Jeffrey N. Miner, Fadi Braiteh, Sonny Gunawan, Aram F. Hezel, Joe Stephenson, Carlos Becerra, Diane P. Leffingwell, David M. Wilson, Morris Sherman
Publikováno v:
Clin Cancer Res
Purpose: To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib, in patients with advanced solid malignancies. Experimental Design: This phase I dose-escalation study included an expan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34a7697aa7ca6757a7d6978c85868d1b
https://pubmed.ncbi.nlm.nih.gov/26644411
https://pubmed.ncbi.nlm.nih.gov/26644411
Autor:
Armin Rieger, Tranh Nguyen, Marta Boffito, Mai Nguyen, Zancong Shen, Voon Ong, Graeme Moyle, Barry D. Quart, Li-Tain Yeh, Vijay Hingorani, Anneke K. Raney, Beth Sheedy, Albrecht Stoehr, Kimberly Manhard
Publikováno v:
Antimicrobial agents and chemotherapy. 54(8)
RDEA806 is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent in vitro activity against wild-type and NNRTI-resistant HIV-1. A phase 2a randomized, double-blind, placebo-controlled, dose-escalating study evaluated the short-ter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8edb08a6aacfdf62d5a490a31566465
https://pubmed.ncbi.nlm.nih.gov/20498326
https://pubmed.ncbi.nlm.nih.gov/20498326
Autor:
Jeffrey N. Miner, Philip K. Tan, David Hyndman, Sha Liu, Cory Iverson, Payal Nanavati, David T. Hagerty, Kimberly Manhard, Zancong Shen, Jean-Luc Girardet, Li-Tain Yeh, Robert Terkeltaub, Barry Quart
Publikováno v:
Arthritis Research & Therapy. 18(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0e815f7e3f446e55f96b3029725e074